DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. senior vice president and Chief Supply Chain Officer Robert Anthony Johnson reported share dispositions that were made to cover tax obligations, not open-market sales. On March 4, 2026, 1,026 common shares were withheld at $13.44 per share, leaving 117,176.146 shares held directly.
On March 3, 2026, two similar tax-withholding transactions occurred, with 3,229 and 4,481 common shares withheld at $13.30 per share. Footnotes explain these shares were retained by the company to satisfy taxes due upon vesting of previously granted restricted and performance-based stock units.
DENTSPLY SIRONA Inc. senior vice president and chief human resources officer Andrea L. Frohning reported tax-related share dispositions tied to vesting equity awards. On March 3 and 4, 2026, a total of 5,657 shares of common stock were withheld to cover tax liabilities at prices between $13.30 and $13.44 per share. These are coded as tax-withholding dispositions, not open-market sales. After the most recent withholding, Frohning directly holds 37,206.252 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. reported that officer Kevin Czerney, its VP and Chief Accounting Officer, had company shares withheld to cover tax obligations from vesting equity awards. On March 3, 2026, tax-withholding dispositions of 527 and 1,197 shares of common stock occurred at prices of $13.30 per share. On March 4, 2026, an additional 328 shares were withheld at $13.44 per share. These transactions relate to the vesting of performance-based and time-based restricted stock units and associated dividend equivalent units and are not open-market sales.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported indirect open-market purchases of the company’s common stock through a trust. On March 2 and 3, the trust bought a total of 50,000 shares at weighted average prices of $14.245 and $14.028 per share.
The trust now holds 50,000 shares, while additional indirect holdings shown include 24,901.284 shares through a family partnership and 21,000 shares in a Gregory Lucier IRA. The filing notes the trust is one where Lucier serves as trustee and beneficiary and that he disclaims beneficial ownership beyond his pecuniary interest.
Johnson Robert Anthony reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported an award of 9,599 shares of common stock at no cost, increasing his directly held stake to 125,912.146 shares. The filing also notes that performance criteria for 1,478 performance-based restricted stock units granted on March 3, 2023 were certified as attained on March 2, 2026, with those units scheduled to vest into common shares on March 3, 2026.
DENTSPLY SIRONA Inc. reported that executive Andrea L. Frohning, SVP and CHRO, acquired 8,861 shares of common stock as a stock award. The shares were received at no cash cost per share, increasing her directly held position to 42,863.252 shares.
According to a footnote, this relates to performance-based restricted stock units granted on March 3, 2023. The issuer’s Compensation Committee certified that the performance criteria were met and 1,478 PRSUs were attained on March 2, 2026, with those PRSUs scheduled to vest into shares on March 3, 2026.
DENTSPLY SIRONA Inc. executive Kevin Czerney, the Vice President and Chief Accounting Officer, reported acquiring 1,478 shares of common stock as a grant or award at a price of $0.00 per share. After this award, his directly owned holdings increased to 29,630.908 shares of the company’s common stock.
The award relates to performance-based restricted stock units granted on March 3, 2023, which were certified as attained on March 2, 2026 after the company met specified performance criteria. According to the award terms, these PRSUs vest and convert into shares of common stock on March 3, 2026.
DENTSPLY SIRONA Inc. director James D. Forbes bought 5,000 shares of common stock in an open-market purchase. The shares were acquired at a price of $13.469 per share on 2026-03-03, giving him direct ownership of 5,000 shares following the transaction.
DENTSPLY SIRONA Inc. director Brian P. McKeon filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing establishes his reporting status as a director of the company but does not report any specific buy or sell transactions.
DENTSPLY SIRONA Inc. director James D. Forbes filed an initial ownership report on Form 3. This filing establishes his status as an insider, including his role as a director of the company. The Form 3 does not report any share purchases or sales, and serves as a baseline disclosure of his insider position.